https://www.optimumcomms.com/wp-content/uploads/2023/06/NovoFund_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-04-29 08:42:482025-04-29 08:45:51Novo Nordisk Foundation expands Challenge Programme outside of Denmark for the first time and significantly increases grants
https://www.optimumcomms.com/wp-content/uploads/2023/06/NovoFund_Logo_300x180px-80x80-1.png
180
300
Healthcare Team
https://www.optimumcomms.com/wp-content/uploads/2024/10/Optimum_Logo-white.svg
Healthcare Team2025-04-29 08:42:482025-04-29 08:45:51Novo Nordisk Foundation expands Challenge Programme outside of Denmark for the first time and significantly increases grants
Cycuria Therapeutics Launches with the Formation of a Distinguished Advisory Board and Significant Public Grant Funding
Cycuria aims to revolutionise treatment of hard-to-treat…

Novo Holdings and EIFO invest €48 million in HealthCap IX to strengthen the Nordic life sciences ecosystem
Novo Holdings and the Export and Investment Fund of Denmark (EIFO)…

Heidelberg Pharma AG: Interim Statement on the First Three Months of Financial Year 2025
Cohort 7 of the clinical trial of HDP-101 in multiple myeloma…

Alis Biosciences launches fund to free over USD$30 billion of capital trapped in listed development-stage life sciences and biotech companies
Significant market inefficiencies have left over USD$30 billion…

Astraveus Strengthens Leadership Team and Board
Jean-Paul Mangeolle joins as Chairman of the Board of Directors
…

Oxolife’s CEO Agnès Arbat receives prestigious EU Women Innovators Prize
Barcelona, Spain – 9 April 2025: Oxolife, the female fertility…

Infinitopes Granted Phase I/IIa Clinical Trial Application Approval to Evaluate Precision Vaccine Targeting Early-Stage Oesophageal Cancer
Revolutionary ‘off-the-shelf’ cancer vaccine designed…

Xeltis successfully passes evaluation phase for €10million investment from European Innovation Council
Xeltis is one of only seven companies to successfully pass…

Novo Holdings posts record Total Income and Investment Returns of DKK 60 billion (€8.0 billion) in 2024, with the Investment Portfolio delivering above-benchmark returns, alongside strong growth at the Novo Group companies
Copenhagen, Denmark – Novo Holdings today announced its financial…

Domain Therapeutics to Present Data on its GPCR Lead Programs at AACR Annual Meeting 2025
Presentation of Phase I clinical results from DT-9081, an…

Heidelberg Pharma to Present Data from its ADC Technology Platforms at AACR Annual Meeting 2025
Ladenburg, Germany, 26 March 2025 – Heidelberg Pharma AG (FSE:…

Gergely Sved appointed CEO of Ellab
27 March 2025 Hillerød, Denmark – Ellab, the leading provider…

Poolbeg to Participate in Key Conferences in March and April 2025
Poolbeg to present at Master Investor Show, BioTrinity &…

Alys Pharmaceuticals Announces Dosing of First Patient in Phase IIa Trial of ALY-101 for Alopecia Areata
Unique siRNA platform, developed with Nobel Prize Laureate…

Novo Holdings participates in €23 million Series A for Tribune Therapeutics to advance next-generation anti-fibrotic therapies
Investment addresses the need for disease-modifying therapies…
We’d love to hear from you
For more information about Optimum Strategic Communications, please get in touch.
Optimum Strategic Communications’ specialist team has an in-depth understanding of how to communicate complex science to investors and corporate stakeholders. Optimum helps life science companies on their journey as they grow and has been trusted by hundreds of healthcare clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York